A5091513177- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Boron Compounds in Chemistry
- Ferroptosis and cancer prognosis
- PARP inhibition in cancer therapy
- Inflammatory Biomarkers in Disease Prognosis
- Child and Adolescent Psychosocial and Emotional Development
- Spondyloarthritis Studies and Treatments
- Gout, Hyperuricemia, Uric Acid
- Venous Thromboembolism Diagnosis and Management
- Cerebral Venous Sinus Thrombosis
- Preterm Birth and Chorioamnionitis
- Neonatal Respiratory Health Research
- Prostate Cancer Diagnosis and Treatment
- Histiocytic Disorders and Treatments
- Fern and Epiphyte Biology
- Plant Diversity and Evolution
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Cancer survivorship and care
- Maternal Mental Health During Pregnancy and Postpartum
Robert S. Peabody Museum of Archaeology
2025
Yale Peabody Museum
2025
Tulane University
2021-2024
University of Tennessee at Knoxville
2021
Women & Infants Hospital of Rhode Island
2006
Providence College
2006
Cleveland Clinic
2004
Objective: Promising results were obtained in an earlier pilot study of a preventive intervention based on the principles interpersonal psychotherapy to reduce risk postpartum major depressive disorder. In this study, authors examined whether would disorder larger sample pregnant women. Method: Ninety-nine women public assistance who assessed be at for depression randomly assigned receive standard antenatal care plus or only. Diagnostic interviews administered 3 months after delivery assess...
<h3>Importance</h3> Uric acid is a waste metabolite produced from the breakdown of purines, and elevated serum uric levels are associated with higher risk hypertension, cardiovascular disease, mortality progression chronic kidney disease (CKD). Treatment hyperuricemia in patients preexisting CKD has not been shown to improve outcomes, but associations acid–lowering therapies development new-onset estimated glomerular filtration rate (eGFR) within reference range no albuminuria unclear....
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
Renal cell carcinoma (RCC), the most prevalent type of kidney cancer, is a significant cause cancer morbidity and mortality worldwide. Antiangiogenic tyrosine kinase inhibitors (TKIs), in combination with immune checkpoint (ICIs), are among first-line treatment options for patients advanced RCC. These therapies target vascular endothelial growth factor receptor (VEGFR) pathway other kinases crucial to proliferation, survival, metastasis. TKIs have yielded substantial improvements...
Abstract Premise Pteridophytes—vascular land plants that disperse by spores—are a powerful system for studying plant evolution, particularly with respect to the impact of abiotic factors on evolutionary trajectories through deep time. However, our ability use pteridophytes investigate such questions—or capitalize ecological and conservation‐related applications group—has been impaired relative isolation neo‐ paleobotanical research communities absence large‐scale biodiversity data sources....
Abstract Background African American men are much more likely than Caucasian to be diagnosed with and die of prostate cancer. Genetic differences play a role. The cBioPortal database reveals that cancer have higher rates CDK12 somatic mutations compared men. However, this does not account for prior treatments, which particularly important in the castrate‐resistant setting. We aimed compare based on circulating tumor DNA (ctDNA) metastatic castration‐resistant (mCRPC) between after exposure...
212 Background: Patients with prostate cancer liver metastases are known to have a worse prognosis. In this study, we evaluated ctDNA in mCRPC (metastatic castration-resistant cancer) patients and without metastases. Methods: A retrospective chart review identified at Tulane Cancer Center Huntsman Institute. Liver were confirmed via molecular or conventional imaging. All had assessed multi-gene panel the Guardant 360 assay. Alterations <0.1% allelic fraction, synonymous alterations,...
Papillary renal cell carcinoma (PRCC) is the most common subtype of non-clear carcinoma. PRCC can be subdivided into types 1 and 2 based on histology, each associated with different genetic mutations. The MET gene commonly altered in type while multiple alterations are involved PRCC. an aggressive cancer a predominance male black patients poor prognosis. Due to its rarity, there was lack convincing prospective data guide treatment; hence, therapies were previously extrapolated from clear...
344 Background: IROC is an expanding multi-institution collaborative database which includes socioeconomic, genomic, pathologic, clinical and laboratory data in metastatic RCC patients (pts), primarily the modern setting. Elevated baseline NLR now established poor prognostic factor renal cell carcinoma (RCC) but currently has limited practical use. We hypothesized that increase of 3 or more (NLR Failure) at 2 months on therapy could be a predictor eventual treatment failure shorter overall...
Warfarin is commonly used for prevention of embolic events. Bleeding the main side effect warfarin. Lingual and sublingual haematoma are rare. In literature, nine cases have so far been reported. We report case a 70-year-old Caucasian woman who developed spontaneous lingual haematomas while on warfarin therapy. Spontaneous rare, but can be potentially life-threatening complications as they cause airway obstruction. To best our knowledge, this first reported earliest after use.
248 Background: mCRPC patients with liver metastases have a poor prognosis and often progress rapidly on variety of treatments. Previously, preliminary ctDNA analyses showed range commonly altered genes in (Ranasinghe et al; 2019). In this follow-up, we evaluated alterations an expanded cohort metastases. Methods: From Tulane Cancer Center, retrospective review was used to identify confirmed metastasis. All were based imaging data. included had multi-gene cancer panel via Guardant 360 assay...
246 Background: TP53, an oncogene implicated in the development of many malignancies, is commonly altered mCRPC. Gain-of-function mutations TP53 confer increased oncogenic properties this gene and play a role The goal study was to characterize somatic mutations, specifically gain-of-function ctDNA mCRPC patients context prior therapies. Methods: A retrospective analysis at Tulane Cancer Center between 2015-2022 performed. All had testing performed with Guardant360 multigene panel assay....
BACKGROUND: The therapeutic benefit of targeting T2/FLAIR in addition to contrast-enhancing (CE) tumor during re-irradiation for recurrent glioma can be attenuated by augmented toxicity. Given its steep dose fall-off and narrow penumbrae, PT minimizes volume brain parenchyma outside target volume, potentially permitting a less toxic delivery large-volume re-irradiation. METHODS: From 2/2011 12/2013, 19 consecutive adult patients with treated at single institution were retrospectively...
230 Background: Somatic alterations change over time in response to treatment and disease progression patients with prostate cancer (PCa). We report ctDNA findings of who died from PCa within 3 months a assessment better characterize fatal disease. Methods: A total 118 specific mortality had been treated at Tulane Cancer Center assessments between 2015 2022. The was assessed by Guardant360 (Guardent Health, Inc) assays identify alterations, pathogenic mutations and/or copy number (CNAs)...
35 Background: Genetic differences between African American and Caucasian patients with advanced prostate cancer may contribute to racial disparities in terms of treatment outcomes survival, hence further exploration is warranted. We assessed ctDNA men the setting CRPC post abiraterone and/or enzalutamide. Methods: From 2015 through 2022 at Tulane Cancer Center, 250 including 50 Americans 200 prior enzalutamide were included. All had via Guardant360. Data both gene mutations types for 73-80...
243 Background: Lutetium-177- PSMA-617 (Lu-177) is a radioligand therapy that delivers radiation to PSMA-expressing cells in patients with advanced prostate cancer. In this study, we aimed analyze ctDNA responders and non-responders after Lu-177 treatments. Methods: Data was retrospectively collected on 31 heavily pre-treated metastatic CRPC who received treatment at Tulane Cancer Center. All fulfilled VISION criteria for all had assessment Guardant 360 within 30 days prior first Lu-177. Of...
253 Background: Approximately 3-5% of advanced prostate cancer patients have pathogenic BRCA2 mutations in germline tests. In this study, we examine the relationship between mutation and somatic changes ctDNA. Methods: Germline screenings were performed by Invitae multi-cancer gene panel which includes 50-84 genes. ctDNA alterations detected Guardant 360 assays report 70-83 All samples collected post-abiraterone and/or enzalutamide (in CRPC patients). Any pathogenic/likely ctDNAs with more...
12128 Background: Early interdisciplinary Palliative Medicine (PM) involvement is known to provide significant benefits when added usual oncology care, however a study by Ferrari et al looking at oncologic patients between 2001 2016 found that only 36% of with cancers very poor prognosis received services. In ASCO provided practice guideline recommending specialty PM services begin within 8 weeks diagnosis. Our aimed assess the integration above recommendation in newly built academic, safety...
Bone marrow infiltration by Kaposi sarcoma (KS) in human immunodeficiency virus (HIV) patients is rare, with only a few cases reported CD4 count greater than 200 cells/ml. To the best of our knowledge, this first case bone involvement HIV-associated KS which 400 In article, we present patient skin, lymph node, bone, pulmonary, gastrointestinal, and despite high count. This highest associated invasion medical literature. A does not protect untreated HIV against aggressive, diffuse KS-related...